Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1: A Randomized, Double-Blind, Placebo-Controlled Study

NCT07128212 is registered in ClinicalTrials.gov with Suzhou Municipal Hospital of Anhui Province as lead sponsor.

NCT NCT07128212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07128212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1: A Randomized, Double-Blind, Placebo-Controlled Study
Lead sponsor
Suzhou Municipal Hospital of Anhui Province
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2021
Completion date
December 31, 2022
Enrollment
401 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral small vessel disease, ischemic white matter lesions (wmil), vascular cell adhesion molecule-1, vcam-1